---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001410"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:57:32.594444+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aptose provides TUS+VEN+AZA triplet clinical update and 2025 milestones

## Summary
- 40mg TUS+VEN+AZA triplet achieved CRs in FLT3-WT and TP53-mutated newly diagnosed AML; no DLTs.
- 80mg TUS dose cohort in TUS+VEN+AZA triplet is currently enrolling.
- Hanmi collaboration expected Q2 2025; $10M advance converting to common stock.
- Raised approx. $37M in 2024; capital structure: 2.14M shares O/S, 1.27M warrants.
- Planned data releases at EHA 2025 and ASH 2025; dose selection for Ph2/3 pivotal.

## SEC filing metadata
- accession: 0001171843-25-001410
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325001410/0001171843-25-001410-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325001410/f8k_031125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001410
- JSON: https://secwatch.observer/filing/0001171843-25-001410.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001410.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.